Legal & General Group Plc Sells 22,110 Shares of Envista Holdings Co. (NYSE:NVST)

Legal & General Group Plc cut its holdings in Envista Holdings Co. (NYSE:NVST - Free Report) by 6.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 341,564 shares of the company's stock after selling 22,110 shares during the period. Legal & General Group Plc owned about 0.20% of Envista worth $6,589,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of NVST. Venturi Wealth Management LLC increased its holdings in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after purchasing an additional 1,638 shares during the period. GAMMA Investing LLC grew its position in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after buying an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Envista during the 4th quarter valued at about $53,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of Envista during the 4th quarter worth about $86,000. Finally, KBC Group NV lifted its stake in shares of Envista by 63.9% in the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock worth $152,000 after acquiring an additional 3,082 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NVST shares. Jefferies Financial Group upped their target price on Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research report on Thursday, January 23rd. New Street Research set a $19.00 target price on Envista in a report on Thursday, March 6th. Morgan Stanley set a $16.00 price target on shares of Envista in a report on Tuesday, April 15th. Wells Fargo & Company set a $19.00 price objective on shares of Envista in a research note on Saturday, March 8th. Finally, JPMorgan Chase & Co. cut their target price on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Envista currently has an average rating of "Hold" and an average price target of $19.96.

Envista Stock Up 0.6 %

NVST stock traded up $0.09 during midday trading on Thursday, reaching $15.81. The company had a trading volume of 266,381 shares, compared to its average volume of 2,488,661. The company has a 50 day moving average of $17.45 and a two-hundred day moving average of $19.13. The company has a market capitalization of $2.72 billion, a P/E ratio of -2.44, a PEG ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a 1 year low of $14.22 and a 1 year high of $23.00. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts expect that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.